Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck cozaar / Hyzaar (losartan, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, Q1 2021
43
Period ended Mar 31, 2021
Change on a year earlier
-39.4%
71 in Q1 2020
History
17 quarters
Since Q1 2017
Sources
12
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cozaar / Hyzaar (losartan, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2021 | Mar 31, 2021 | 43 | -39.4% | Form 10-Q (filed 2021-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 225 | +4.2% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 41 | -29.3% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 49 | -31.9% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 71 | -26.0% | Form 10-Q (filed 2021-05-05) ↗ |
| Q4 2019 | Dec 31, 2019 | 216 | +20.7% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 58 | -18.3% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 72 | -11.1% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 96 | -21.3% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 179 | +44.4% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 71 | -44.5% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 81 | -31.9% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 122 | +8.9% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 124 | – | Form 10-K (filed 2020-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 128 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 119 | – | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 112 | – | Form 10-Q (filed 2018-05-08) ↗ |
Breakdown
What makes up cozaar / hyzaar (losartan, legacy pre-organon spin-off) — worldwide sales ($m)
Cite this data
StockData. (2026). Merck Cozaar / Hyzaar (losartan, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M), quarterly Q1 2017–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_cozaar_hyzaar
See every metric in the Merck KPI table. Data updated Oct 26, 2026.